Drug-eluting stents - Insights from invasive imaging technologies

Circulation Journal

Volumn 73, Issue 8, 2009, Pages 1371-1380

  Honda, Yasuhiro ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary artery disease; Drug eluting stent (DES); Intravascular ultrasound; Restenosis; Thrombosis

Indexed keywords

POLYMER; RAPAMYCIN; ZOTAROLIMUS;

ANGIOGRAPHY; ANGIOSCOPY; ARTERY WALL; BARE METAL STENT; BIOMECHANICS; DRUG ELUTING STENT; HUMAN; IMAGING; INTRAVASCULAR ULTRASOUND; OPTICAL COHERENCE TOMOGRAPHY; RESTENOSIS; REVIEW; SAFETY;

CATHETERIZATION; DIAGNOSTIC IMAGING; DRUG-ELUTING STENTS; ENDOSCOPY; HUMANS;

EID: 69049084809     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0377     Document Type: Review

References (67)

1. Hibi K, Suzuki T, Honda Y, Hayase M, Bonneau HN, Yock PG, et al. Quantitative and spatial relation of baseline atherosclerotic plaque burden and subsequent in-stent neointimal proliferation as determined by intravascular ultrasound. Am J Cardiol 2002; 90: 1164-1167. (Pubitemid 35335614)
2. Weissman NJ, Wilensky RL, Tanguay JF, Bartorelli AL, Moses J, Williams DO, et al. Extent and distribution of in-stent intimai hyperplasia and edge effect in a non-radiation stent population. Am J Cardiol 2001; 88: 248-252. (Pubitemid 32721950)
3. Hirohata A, Morino Y, Ako J, Sakurai R, Buchbinder M, Caputo RP, et al. Comparison of the efficacy of direct coronary stenting with sirolimus-eluting stents versus stenting with predilation by intravascular ultrasound imaging (from the DIRECT trial). Am J Cardiol 2006; 98: 1464-1467. (Pubitemid 44779474)
4. Sakurai R, Bonneau HN, Honda Y, Fitzgerald PJ. Intravascular ultrasound findings in ENDEAVOR II and ENDEAVOR III. Am J Cardiol 2007; 100: 71M-76M. (Pubitemid 47576039)
5. Hong MK, Mintz GS, Lee CW, Song JM, Han KH, Kang DH, et al. Pachtaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: A serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation 2003; 107: 517-520.
6. Weissman NJ, Koglin J, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: A serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005; 45: 1201-1205. (Pubitemid 40523137)
7. Sakurai R, Hongo Y, Yamasaki M, Honda Y, Bonneau HN, Yock PG, et al. Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). Am J Cardiol 2007; 100: 818-823.
8. Aoki J, Colombo A, Dudek D, Banning AP, Drzewiecki J, Zmudka K, et al. Peristent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: Insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation 2005; 112: 3876-3883. (Pubitemid 43739485)
9. Kuroda N, Kobayashi Y, Nameki M, Kuriyama N, Kinoshita T, Okuno T, et al. Intimai hyperplasia regression from 6 to 12 months after stenting. Am J Cardiol 2002; 89: 869-872. (Pubitemid 34241471)
10. Hur SH, Ako J, Shimada Y, Tsujino I, Hassan AH, Abizaid A, et al. Two-year intravascular ultrasound observations in diabetic patients treated with single and double dose sirolimus-eluting stents: Results of the double dose diabetes (3D) study. J Invasive Cardiol 2008; 20: 411-416.
11. Aoki J, Abizaid AC, Serruys PW, Ong AT, Boersma E, Sousa JE, et al. Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. J Am Coll Cardiol 2005; 46: 1670-1676. (Pubitemid 41531621)
12. Carrozza JP Jr, Hosley SE, Cohen DJ, Baim DS. In vivo assessment of stent expansion and recoil in normal porcine coronary arteries: Differential outcome by stent design. Circulation 1999; 100: 756-760.
13. Regar E, Schaar J, Serruys PW. Images in cardiology: Acute recoil in sirolimus eluting stent: Real time, in vivo assessment with optical coherence tomography. Heart 2006; 92: 123. (Pubitemid 43021879)
14. de Ribamar Costa J Jr, Mintz GS, Carlier SG, Fujii K, Sano K, Kimura M, et al. Intravascular ultrasound assessment of drug-eluting stent expansion. Am Heart J 2007; 153: 297-303. (Pubitemid 46096874)
15. Koo BK, Waseda K, Ako J, Hasegawa T, Shimohama T, Nakatani D, et al. Incidence of diffuse and focal chronic stent recoil after implantation of current generation bare-metal and drug-eluting stents. Int J Cardiol 2009 [Epub ahead of print].
16. Koo BK, Yamasaki M, Ako J, Waseda K, Honda Y, Fitzgerald PJ, et al. Intravascular ultrasound analysis of small-vessel lesions treated with novel ultra-low profile, guidewire-based self-expanding stent system. J Invasive Cardiol 2008; 20: 647-650.
17. Miyazawa A, Ako J, Hassan A, Hasegawa T, Abizaid A, Verheye S, et al. Analysis of bifurcation lesions treated with novel drug-eluting dedicated bifurcation stent system: Intravascular ultrasound results of the AXXESS PLUS trial. Catheter Cardiovasc Interv 2007; 70: 952-957.
18. Hasegawa T, Ako J, Koo BK, Miyazawa A, Sakurai R, Chang H, et al. Analysis of left main coronary artery bifurcation lesions treated wim biolimus-eluting DEVAX AXXESS plus nitinol self-expanding stent: Intravascular ultrasound results of the AXXENT trial. Catheter Cardiovasc Interv 2009; 73: 34-41.
19. Verheye S, Agostoni P, Dubois CL, Dens J, Ormiston J, Worthley S, et al. 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: The DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study. J Am Coll Cardiol 2009; 53: 1031-1039.
20. Takebayashi H, Mintz GS, Carlier SG, Kobayashi Y, Fujn K, Yasuda T, et al. Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation. Circulation 2004; 110: 3430-3434. (Pubitemid 39602221)
21. Sano K, Mintz GS, Carlier SG, Fujii K, Takebayashi H, Kimura M, et al. Volumetric intravascular ultrasound assessment of neointimal hyperplasia and nonuniform stent strut distribution in sirolimus-eluting stent restenosis. Am J Cardiol 2006; 98: 1559-1562.
22. Hasegawa T, Waseda K, Ako J, Sakurai R, Hongo Y, Wijns W, et al. Nonuniform strut distribution is associated with more neointimal hyperplasia after ABT-578 eluting stent implantation: A 3-D IVUS analysis from the ENDEAVOR 2 trial. J Am Coll Cardiol 2006; 47: 2B.
23. Miyazawa A, Ako J, Hongo Y, Hur SH, Tsujino I, Courtney BK, et al. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: Intravascular ultrasound results from ENDEAVOR III. Am Heart J 2008; 155: 108-113. (Pubitemid 350234763)
24. Sakurai R, Courtney BK, Yamasaki M, Tsujino I, Waseda K, Hasegawa T, et al. Neointimal hyperplasia patterns among 3 drug-eluting stents: A comparative intravascular ultrasound analysis of everolimus-, sirolimus-, and paclitaxel-eluting stents. Circulation 2007; 116: 615.
25. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52: 333-342. (Pubitemid 352001347)
26. Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: Evaluated by optical coherence tomography. Eur Heart J 2007; 28: 961-967. (Pubitemid 47343895)
27. Takano M, Inami S, Jang JK, Yamamoto M, Murakami D, Seimiya K, et al. Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation. Am J Cardiol 2007; 99: 1033-1038. (Pubitemid 46560470)
28. Yao ZH, Matsubara T, Inada T, Suzuki Y, Suzuki T. Neointimal coverage of sirolimus-eluting stents 6 months and 12 months after implantation: Evaluation by optical coherence tomography. Chin Med J 2008; 121: 503-507.
29. Katoh H, Shite J, Shinke T, Matsumoto D, Tanino Y, Ogasawara D, et al. Delayed neointimalization on sirolimus-eluting stents: 6-month and 12-month follow up by optical coherence tomography. Circ J 2009; 73: 1033-1037.
30. Kubo T, Imanishi T, Kitabata H, Kuroi A, Ueno S, Yamano T, et al. Comparison of vascular response after sirolimus-eluting stent implantation between patients with unstable and stable angina pectoris: A serial optical coherence tomography study. J Am Coll Cardiol Img 2008; 1: 475-484. (Pubitemid 351998679)
31. Moore P, Barlis P, Spiro J, Ghimire G, Roughton M, Mario CD, et al. A randomized optical coherence tomography study of coronary stent strut coverage and luminal protrusion with rapamycin-eluting stents. J Am Coll Cardiol Intv 2009; 2: 437-444.
32. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, et al. Incomplete neointimal coverage of sirolimus-eluting stents: Angioscopic findings. J Am Coll Cardiol 2006; 47: 2108-2111.
33. Oyabu J, Ueda Y, Ogasawara N, Okada K, Hirayama A, Kodama K. Angioscopic evaluation of neointima coverage: Sirolimus drug-eluting stent versus bare metal stent. Am Heart J 2006; 152: 1168-1174. (Pubitemid 44854799)
34. Takano M, Ohba T, Inami S, Seimiya K, Sakai S, Mizuno K. Angioscopic differences in neointimal coverage and in persistence of thrombus between sirolimus-eluting stents and bare metal stents after a 6-month implantation. Eur Heart J 2006; 27: 2189-2195. (Pubitemid 44412833)
35. Awata M, Kotani J, Uematsu M, Morozumi T, Watanabe T, Onishi T, et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation 2007; 116: 910-916. (Pubitemid 47300915)
36. Takano M, Yamamoto M, Xie Y, Murakami D, Inami S, Okamatsu K, et al. Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angioscopy. Heart 2007; 93: 1533-1536. (Pubitemid 350205543)
37. Higo T, Ueda Y, Oyabu J, Okada K, Nishio M, Hirata A, et al. Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: An angioscopic study. J Am Coll Cardiol Img 2009; 2: 616-624.
38. Nakazawa G, Vorpahl M, Finn AV, Narula J, Virmani R. One step forward and two steps back with drug-eluting-stents: From preventing restenosis to causing late thrombosis and nouveau atherosclerosis. J Am Coll Cardiol Img 2009; 2: 625-628.
39. Fuke S, Maekawa K, Kawamoto K, Saito H, Sato T, Hioka T, et al. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ J 2007; 71: 220-225. (Pubitemid 46182696)
40. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005; 46: 231-236. (Pubitemid 40966848)
41. Hamilos MI, Ostojic M, Beleslin B, Sagic D, Mangovski L, Stojkovic S, et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol 2008; 51: 2123-2129. (Pubitemid 351721001)
42. Kim JW, Suh SY, Choi CU, Na JO, Kim EJ, Rha SW, et al. Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus Paclitaxel-eluting stent. J Am Coll Cardiol Intv 2008; 1: 65-71.
43. Kim JW, Seo HS, Park JH, Na JO, Choi CU, Lim HE, et al. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: Differential recovery of coronary endothelial dysfunction. J Am Coll Cardiol 2009; 53: 1653-1659.
44. Obata JE, Kitta Y, Takano H, Kodama Y, Nakamura T, Mende A, et al. Sirolimus-eluting stent implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery in patients with acute myocardial infarction. J Am Coll Cardiol 2007; 50: 1305-1309. (Pubitemid 47446093)
45. Serruys PW, Degertekin M, Tanabe K, Russell ME, Guagliumi G, Webb J, et al. Vascular responses at proximal and distal edges of paclitaxel-eluting stents: Serial intravascular ultrasound analysis from the TAXUS II trial. Circulation 2004; 109: 627-633. (Pubitemid 38198870)
46. Waseda K, Ako J, Kaneda H, Miyazawa A, Shimada Y, Morino Y, et al. Effect of lumen narrowing within sirolimus-eluting stents on proximal and distal vessel segments. Circ J 2008; 72: 534-537.
47. Kaneda H, Ako J, Kataoka T, Miyazawa A, Terashima M, Ikeno F, et al. Effect of lumen narrowing within coronary stents on proximal and distal vessel segments following bare metal stent implantation. Am J Cardiol 2005; 96: 376-378. (Pubitemid 41058862)
48. Tanabe K, Serruys PW, Degertekin M, Guagliumi G, Grube E, Chan C, et al. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: Comparison with bare metal stents by serial intravascular ultrasound analyses: Data from the randomized TAXUS-II trial. Circulation 2004; 109: 196-200. (Pubitemid 38114139)
49. Waseda K, Miyazawa A, Ako J, Hasegawa T, Tsujino I, Sakurai R, et al. Comparison of vascular response between zotarolimus-eluting stent and paclitaxel-eluting stent implantation: IVUS results from the ENDEAVOR IV trial. JAm Coll Cardiol Intv 2009 (in press).
50. Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007; 100: 36M-44M. (Pubitemid 47576035)
51. Hur SH, Ako J, Honda Y, Sudhir K, Fitzgerald PJ. Late-acquired incomplete stent apposition: Morphologic characterization. Cardiovasc Revasc Med 2009 (in press).
52. Tanigawa J, Barlis P, Dimopoulos K, Dalby M, Moore P, Di Mario C. The influence of strut thickness and cell design on immediate apposition of drug-eluting stents assessed by optical coherence tomography. Int J Cardiol 2009; 134: 180-188.
53. Hassan AK, Bergheanu SC, Stijnen T, van der Hoeven BL, Snoep JD, Plevier JW, et al. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur Heart J 2009 [Epub ahead of print].
54. Ako J, Morino Y, Honda Y, Hassan A, Sonoda S, Yock PG, et al. Late incomplete stent apposition after sirolimus-eluting stent implantation: A serial intravascular ultrasound analysis. J Am Coll Cardiol 2005; 46: 1002-1005. (Pubitemid 41316506)
55. Doi H, Maehara A, Mintz GS, Tsujita K, Kubo T, Castellanos C, et al. Classification and potential mechanisms of intravascular ultrasound patterns of stent fracture. Am J Cardiol 2009; 103: 818-823.
56. Hong MK, Mintz GS, Lee CW, Park DW, Choi BR, Park KH, et al. Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation. Eur Heart J 2006; 27: 1305-1310.
57. Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Yasuda T, et al. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation 2004; 109: 1085-1088. (Pubitemid 38332610)
58. Sonoda S, Morino Y, Ako J, Terashima M, Hassan AH, Bonneau HN, et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: Serial intravascular ultrasound analysis from the sirius trial. J Am Coll Cardiol 2004; 43: 1959-1963. (Pubitemid 38686788)
59. Alfonso F, Suarez A, Perez-Vizcayno MJ, Moreno R, Escaned J, Banuelos C, et al. Intravascular ultrasound findings during episodes of drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 50: 2095-2097. (Pubitemid 350087569)
60. Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G, et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: An intravascular ultrasound study. J Am Coll Cardiol 2005; 45: 995-998. (Pubitemid 40432428)
61. Okabe T, Mintz GS, Buch AN, Roy P, Hong YJ, Smith KA, et al. Intravascular ultrasound parameters associated with stent thrombosis after drug-eluting stent deployment. Am J Cardiol 2007; 100: 615-620. (Pubitemid 47223136)
62. Sakurai R, Ako J, Morino Y, Sonoda S, Kaneda H, Terashima M, et al. Predictors of edge stenosis following sirolimus-eluting stent deployment (a quantitative intravascular ultrasound analysis from the SIRIUS trial). Am J Cardiol 2005; 96: 1251-1253. (Pubitemid 41505403)
63. Costa MA, Angiolillo DJ, Tannenbaum M, Driesman M, Chu A, Patterson J, et al. Impact of stent deployment procedural factors on long-term effectiveness and safety of sirolimus-eluting stents (final results of the multicenter prospective STLLR trial). Am J Cardiol 2008; 101: 1704-1711.
64. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, et al. TAXUS III Trial: In-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107: 559-564. (Pubitemid 36176804)
65. Sakurai R, Ako J, Hassan AH, Bonneau HN, Neumann FJ, Desmet W, et al. Neointimal progression and luminal narrowing in sirolimus-eluting stent treatment for bare metal in-stent restenosis: A quantitative intravascular ultrasound analysis. Am Heart J 2007; 154: 361-365. (Pubitemid 47069132)
66. Roy P, Steinberg DH, Sushinsky SJ, Okabe T, Pinto Slottow TL, Kaneshige K, et al. The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. Eur Heart J 2008; 29: 1851-1857.
67. Park SJ, Kim YH, Park DW, Lee SW, Kim WJ, Suh J, et al. Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis. Circ Cardiovasc Intervent 2009 [E-pub ahead of print].